Official Title
The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection
Brief Summary

A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.

Detailed Description

In this study, the investigators hypothesize a positive effect of probiotic on the gut
microbiome that could led to produce a less severe clinical evolution of the disease.

Completed
COVID-19
Coronavirus Infection

Dietary Supplement: Probiotic

Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.

Eligibility Criteria

Inclusion Criteria:

- Patients with a confirmed diagnosis of SARS-Cov.2 infection using the PCR and that
require admission to the hospitalization area.

Exclusion Criteria:

- Inability or refusal to sign informed consent.

- Allergy or intolerance to the intervention product or its components.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Spain
Locations

Hospital Universitario del Vinalopó
Elche, Alicante, Spain

Hospital Universitario de Torrevieja
Torrevieja, Alicante, Spain

Vicente Navarro, Principal Investigator
Hospital universitario del Vinalopo, Elche, Spain

NCT Number
Keywords
Probiotic
MeSH Terms
Infections
COVID-19
Coronavirus Infections